Condition: Prostate Cancer · Sponsor: Novartis Pharmaceuticals
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| VA Greater LA Healthcare System | Los Angeles, California, United States | Recruiting |
| VA Palo Alto Health Care System | Palo Alto, California, United States | Recruiting |
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| Sansum Clinic | Santa Barbara, California, United States | Recruiting |
| Saint Johns Cancer Institute | Santa Monica, California, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Recruiting |
| University Cancer and Blood Center LLC | Athens, Georgia, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| University of Kansas Hospital | Kansas City, Kansas, United States | Recruiting |
| East Jefferson Hospital | Metairie, Louisiana, United States | Recruiting |
+ 69 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780670